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Abstract
Background: Healthcare-associated infections (HAIs) are common and increase morbidity, mortality, and healthcare
costs. Their control continues to be an unresolved issue worldwide. HAIs epidemiology shows sex/gender
differences. Thus the lack of consideration of sex/gender in Cochrane reviews will limit their applicability and
capacity to support informed decisions. This study aims to describe the extent to which Cochrane reviews of
interventions for preventing HAIs consider sex and gender.
Methods: Methodology study appraising Cochrane reviews of interventions to prevent HAIs. Search methods:
Cochrane Database of Systematic Reviews from 1995 (launch of the journal) to 31 December 2016. Two authors
independently extracted data with EPPI-Reviewer 4 software, and independently appraised the sex/gender content
of the reviews with the Sex and Gender Appraisal Tool for Systematic Reviews (SGAT-SR).
Results: This study included 113 reviews assessing the effects of interventions for preventing HAIs. 100 reviews
(88%) used at least one sex or gender-related term. The terminology used was heterogeneous, being “sex” the term
used in more reviews (51%). No review defined neither sex nor gender. Thus we could not assess the definitions
provided. Consideration of sex and gender was practically absent in the included reviews; in fact, no review met all
the applicable items of the SGAT-SR, and 51 reviews (50%) fulfilled no item. No review provided a complete
description of the sex and the gender of the samples of the included studies. Only ten reviews (10%) planned to
perform sex- and gender-based analysis and only three (3%) could complete the analysis. The method chosen was
always the subgroup analysis based on sex (one review) or gender (two reviews). Three reviews (3%) considered
sex or gender-related findings in the conclusions.
Conclusion: Consideration of sex and gender in Cochrane reviews of interventions for preventing HAIs was
practically absent. This lack of attention to sex and gender reduces the quality of Cochrane reviews, and their
applicability for all people: women and men, boys and girls, and people of diverse gender identities. Cochrane
should attempt to address the shortfalls detected.
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Background
Health inequality and health inequity
‘Health inequality’ and ‘health inequity’ are commonly con-
fused terms, although they have different meanings. Health
inequalities refer to the differences in health status or in the
distribution of health determinants between different popu-
lations (e.g., racial, ethnic, sex, gender, sexual orientation, or
socioeconomic groups) [1]. On the other hand, ‘health in-
equities’, also known as ‘health disparities’ [2], are avoidable
and unfair differences in health across socioeconomic,
demographic and geographic factors [1–6]. According to
the World Health Organization (WHO) Commission on So-
cial Determinants of Health, health inequity is caused by
the following interacting factors: a) the socioeconomic and
political context, b) the social position, b) the material cir-
cumstances, and d) the health system [7].
To reduce health inequities both within and between
countries remains a priority on the agenda of international
organisations, such as the WHO, and local, regional and na-
tional governments [8, 9]. The design and implementation of
health care interventions and health programmes should
apply an “equity lens” to ensure that benefits reach the most
hard-to-reach segments of the population and to avoid
intervention-generated inequalities [10, 11]. See Add-
itional file 1 for definitions of key terms.
The relevance of sex and gender in health
Sex, gender, or sexual orientation are characteristics that
may contribute to health inequalities and health inequities
[5, 10, 12, 13]. The concepts of sex and gender are distinct
but interrelated [14]. According to the Canadian Institutes of
Health Research, every cell is sexed, and every person is gen-
dered [15]. Sex, usually defined as female or male, refers to a
number of biological characteristics in humans and animals
[16]. Sex is linked with physical and physiological features,
such as chromosomes, gene expression, hormone function
and reproductive/sexual anatomy [16, 17].
On the other hand, gender refers to the social roles, be-
haviours, expressions and identities of girls, women, boys,
men, and gender diverse people [16, 17]. Consequently,
gender influences how people perceive themselves and
each other, how they behave and interact, and how power
and resources distribute in society [16, 17].
Sex and gender are usually conceptualised as binary fac-
tors. Thus, analyses often consider male/female for sex, as
well as masculine/feminine for gender [16, 17]. However,
this may not reflect the reality, as the attributes of gender
are multidimensional, dynamic, and interactive [18]. The
term ‘sex/gender’ highlights this ‘entanglement’ of the bio-
logical and the social [17, 19, 20].
Biological and gender-based differences result in differ-
ential health risks, disease incidence, and health service
needs [10]. Consequently, sex and gender interactions can
influence health and well-being in a variety of ways [16].
First, pharmacokinetics and pharmacodynamics of drugs
differ between sexes, resulting in differential adverse event
profiles and further affecting treatment outcomes [21–23].
Secondly, sex and gender both affect environmental and
occupational risks, risk-taking behaviours, access to health
care, health care-seeking behaviour, health care utilisation,
and perceived experience with health care, and thus, dis-
ease prevalence and treatment outcomes [16, 24].
Consideration of sex and gender in research
The consideration of sex and gender in research is relevant
for many reasons, such as for warranting scientific rigour, for
reducing and enhancing the effectiveness of healthcare inter-
ventions, for promoting an informed-decision making, and
for addressing inequities in health [17, 25–27]. The absence
of consideration of sex and gender in research limits the ex-
ternal validity of research findings and their applicability for
women, but also for men [16].
Various stakeholders (e.g., journal editors, research fun-
ders, policymakers) agree that sex and gender matter to
health outcomes [16]. As an example, the National Insti-
tutes of Health (NIH) Revitalization Act of 1993 in the
United States of America (USA) required NIH-funded clin-
ical trials to include women and minorities as participants
and to assess outcomes by sex and race or ethnicity [28].
Also, other relevant stakeholders are asking systematic re-
views (SRs) to determine the evidence of differential effects
across age, sex and socioeconomic status [29]; this is the
case of NICE (National Institute for Health and Care Excel-
lence) [30], or the PRISMA statement [31].
However, research design, reporting, and implementa-
tion, and general science communication often neglect
sex and gender differences [14, 16, 17, 25, 26, 32–35] and
policies attempting to solve this problem, such as the NIH
policies cited above, have not resulted in significant in-
creases in reporting results by sex, race, or ethnicity [36].
Methods to consider sex and gender in systematic
reviews
A SR is a review that departs from a clear question and
follows rigorous and explicit methods in all its stages,
that is, from the identification of the studies to the ana-
lysis of the data [37].
SRs are essential tools to transfer research knowledge
into evidence-informed policy and practice [29, 38, 39].
Also, SRs are crucial in the promotion of health equity as
they help to determine the effects of interventions across
studies conducted in a variety of settings and populations,
which allows for the exploration of both prognostic fac-
tors and treatment-covariate interactions [4, 29, 40–42].
Decision-makers are interested in health equity as one of
the considerations for decision-making, as they need to
know the effects of interventions in the overall population
and across population groups [5, 43]. Considering sex and
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gender in SRs is a significant step forward in determining
to whom the evidence applies, which is critical to make
sound clinical and policy decisions [33].
Sex- and gender-based analysis (SGBA) is the analytical
approach that incoporates the sex and gender perspective
into health research, policies, and programmes, and in health
planning and decision-making [16]. SGBA systemically in-
quiries about biological (sex-based) and socio-cultural (gen-
der-based) differences between women and men, and boys
and girls, without presuming that there are disparities [44].
In the context of SRs, SGBA is any analytical framework
aiming to promote the consideration of sex and gender
properly within SRs, so they have the potential to expand
their findings for all people: women and men, boys, girls,
and people of diverse gender identities.
There are several methodological approaches for address-
ing factors related to equity (sex and gender among them) in
SRs, such as performing subgroup analysis or performing
targeted analyses of sex/gender populations [4].
Consideration of sex and gender in Cochrane reviews
Cochrane is an international organisation that prepares
SRs to support people in making well-informed deci-
sions about health care (36). Although the extent to
which current Cochrane reviews consider sex and gen-
der is not well known, some studies suggest that there is
much room for improvement. To our knowledge, only
the study by Doull et al. [14] has evaluated the consider-
ation of sex and gender in Cochrane reviews. This study
concluded that SGBA was generally absent in a random
sample of 38 Cochrane reviews published before April
2007 in cardiovascular health.
Moreover, Cochrane reviews seem to rarely assess
whether interventions have intended or unintended effects
on health equity [29]; according to another study, only 1%
of a random sample of Cochrane reviews assessed differ-
ences in the effectiveness of interventions across socioeco-
nomic or demographic factors [45]. This shortfall is also
present in non-Cochrane SRs. In fact, the analysis or re-
port of equity issues, [38, 46–49], and sex/gender in par-
ticular [17, 25, 26, 33, 35], is infrequent in SRs.
There are several obstacles to consider sex/gender in
any type of SRs, such as how the included studies defined
sex and gender, the methodological difficulties in measur-
ing and analysing sex and gender, the availability of data
to perform sex and gender analysis, and also the quality of
this data [33]. As an example, the studies included in SRs
usually do not report about the inclusion of specific popu-
lations or, if they do, they may not assess variation in ef-
fects across critical characteristics, such as sex, age,
ethnicity or socioeconomic status [5]. Moreover, sex and
gender are highly interrelated, and it is sometimes difficult
to attribute particular male-female differences to either
sex or gender alone [24]. Consequently, SRs do not clearly
identify to whom the research results apply and do not
present adequate data and analyses about health equity
factors, including sex and gender [34, 40, 50–52]. A
proper SGBA framework can help in determining external
validity—to whom a particular body of evidence applies
and to what degree there is sufficient evidence to general-
ise results [14].
The Sex/Gender Methods Group, a subgroup of the
Campbell and Cochrane Equity Methods Group [53],
was established in December 2005. One of its aims is to
develop methods and tools to integrate sex and gender
in the development and reporting of research synthesis
[54]. Cochrane Madrid is making this a priority, and this
article describes our first step to promote the application
of an “equity lens” to Cochrane reviews.
Healthcare-associated infections: a public health problem
Healthcare-associated infections (HAIs) are infections ac-
quired as a result of the delivery of health care [55]. HAIs
represent a public health problem worldwide, as about 6
and 4% of the hospitalised patients in Europe and the U.
S, respectively, have at least one HAI [56, 57]. Rates of
HAIs seem to be even higher in low or middle-income
countries [58]. HAIs increase morbidity (prolonged hos-
pital stay and worse prognosis) [59], mortality [59, 60],
and healthcare costs [59, 61, 62]. Finally, there can be lim-
ited options for treating HAIs caused by certain
drug-resistant organisms, such as methicillin-resistant
Staphylococcus aureus (MRSA) [56, 57, 63].
Role of sex and gender in infectious diseases
transmission and outcomes
Traditionally, little attention has been paid to sex and
gender differences in infectious diseases [24]. However,
both sex and gender can affect infectious diseases inci-
dence, duration, severity, and mortality through several
pathways [24].
There are biological differences between sexes that
affect infectious diseases. For example, pregnant and lac-
tating women represent a high-risk group for many infec-
tious diseases [24], or females have an increased risk of
catheter-associated urinary tract infection (CAUTI) due to
anatomy that facilitates the bacterial contamination of the
catheter. On the other hand, the vulnerability to infections
differs between sexes due to differences in their immune
systems; in this line, pre-menopausal females seem to have
a natural advantage under septic conditions [64–69],
which may be explained by the role of sex steroids, that
change the host immune function, alter genes and modify
behaviours that influence susceptibility and resistance to
infection [69]. However, a recent SR concluded that the
impact of sex on sepsis outcomes remains equivocal [70].
Finally, males may present higher overall HAIs prevalence,
thirty-day mortality, and one-year mortality [71].
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Gender differences in behaviours, activities, exposures,
and access to resources and decision-making affect
transmission and outcomes for different HAIs [24]. For
example, women are less likely to receive antibiotics
within 3 hours of the diagnostic of sepsis, as compared
to men [72].
Why this study is important
Sex and gender are necessary to understand the trans-
mission of infectious diseases. The integration of a sex/
gender perspective into SRs of interventions to control
the transmission of HAIs is a new and challenging area
but critical to defining successful infection control pro-
grammes [24].
Although we need more research to understand better
how sex and gender interact with HAIs, there is enough
knowledge available to justify the inclusion of a sex/gender
perspective in research and programmes for HAIs. How-
ever, infection control strategies in the healthcare setting
do not often consider sex and gender, and thus, they are
generally the same for males or females [24, 73].
To consider sex and gender in Cochrane reviews of in-
terventions to prevent HAIs is important. First, it will
allow for the identification of the most effective and safest
interventions for women and men. Second, it will contrib-
ute to the reduction of health inequities between men and
women, and thereby promote human rights [24]. Third,
the consideration of sex and gender in Cochrane reviews
will help an informed-decision making for women and
men. Fourth, the findings of our study will contribute to
promoting the incorporation of a sex/gender perspective
into Cochrane reviews of any topic.
We chose to focus our study on Cochrane reviews for
several reasons. First, we foresaw that a high number of
Cochrane reviews had evaluated infection control inter-
ventions [74]. Second, a wide range of Cochrane Review
Groups publishes Cochrane reviews of infection control
interventions, which gives an overview of the general ap-
proach of Cochrane as an organisation towards sex and
gender. Third, Cochrane reviews are recognised as a reli-
able source of evidence worldwide and have a high impact
on decision making, for example, through the consider-
ation of Cochrane reviews in clinical guidelines [75–77],
or in the medical policy documents of private health in-
surers [78]. As an example, the percentage of Cochrane
reviews used in WHO guidelines have been steadily rising,
and so far for 2016, Cochrane reviews have been included
in 90% of the WHO guidelines [77]. However, if Cochrane
reviews do not consider sex and gender, they will not be
able to generate evidence that applies to all the people that
can benefit from the research findings. Thus, Cochrane re-
views may not be useful for policy-makers [29] who seek
information on the distribution of effects in the popula-
tion [48, 79], or may even lead to the implementation of
policies and programs which inadvertently increase health
inequities [80, 81].
Study aims
The general aim of this study was to describe the extent
to which Cochrane reviews of interventions for prevent-
ing HAIs consider sex and gender. The specific objec-
tives were the following.
Objective 1. To describe and assess the terminology
and definitions used for sex and gender.
Objective 2. To determine the content of the reviews
about sex and gender.
Objective 3. To describe the SGBA of the reviews.
Objective 4. To assess whether the review conclusions
considered the sex- and gender-related findings.
Methods
Study design
Methodology study, that is, a study that assesses the
methods used in randomised trials, other healthcare
evaluations or systematic reviews [82].
We did not register this study in PROSPERO database
because it did not meet the inclusion criteria, mainly be-
cause this is not a systematic review [83]. Our research
does not adhere to any reporting statement as to our
knowledge there is no guidance for reporting method-
ology studies.
Criteria for considering reviews for this study
Types of reviews that were eligible
Cochrane reviews published from 1995 (launch of the
journal) until 31st December 2016 that evaluated the ef-
fects of interventions for preventing HAIs. The review
had to be defined as a ‘published review’ (not at protocol
nor title stage), an ‘active review’ (not withdrawn), and
as an ‘intervention review’, that is, a review assessing the
effects (benefits, harms or both) of health care or health
policy interventions [84]. Thus, we excluded the
remaining types of Cochrane reviews: methodology re-
views, diagnostic reviews, overviews of reviews, progno-
sis reviews, and qualitative reviews.
Participants: the review must have considered any
healthcare consumer in risk of healthcare-associated col-
onisation or HAI, except for reviews focusing on neonates,
pre-terms, low birth weight or immunocompromised pa-
tients, due to the epidemiological peculiarities of these
participants. We also excluded reviews focusing on the
prevention of infections in healthcare professionals. All
healthcare settings were eligible.
Interventions: any strategy, pharmacological or not,
aimed at preventing any healthcare-associated colonisa-
tion or infection. Additional file 2 details the eligible inter-
ventions. The review could consider any comparator, that
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is, an inactive comparator (such as doing nothing, use of
placebo, or use of a sham intervention), or an active one
(such as a pharmacological intervention, or a
non-pharmacological intervention, for example, an educa-
tional or organisational one).
Outcomes: the review must have planned to assess at
least one of the following outcomes: (a) occurrence of
HAIs; (b) occurrence of colonisations; (c) mortality due
to HAI; (d) total mortality; (e) resistance to antimicro-
bials; or (f ) any surrogate measure of HAI, such as fever,
positive culture, or antibiotic use. The review had to
consider at least one of the previous outcomes in the
“Types of outcome measures” section (as a primary or
secondary outcome) or had to present results about any
of these outcomes (“Results” section).
Search methods for identification of reviews
We searched the Cochrane Database of Systematic Re-
views (CDSR) looking for all the Cochrane interventions
reviews active and published from 1995 (launch of the
journal) until 31st December 2016. Additional file 3 de-
tails the full search strategy. We used EPPI-Reviewer 4
software [85] to create the database of reviews.
Selection of reviews
Two authors (JLA and SCN or ES) screened each title
and abstract independently to select potentially eligible
reviews. If there was any uncertainty based on this infor-
mation, we obtained the full-text review for further as-
sessment. Two authors (JLA and SCN or ES or AFC)
independently assessed the eligibility of the retrieved full
texts and resolved disagreements by discussion. If there
was no consensus, we consulted a third author (JZ). We
used EPPI-Reviewer 4 software [85] to implement the se-
lection process. We piloted the selection process with
100 records. We created a PRISMA flowchart [86] de-
scribing the results of the selection process.
Data extraction
We designed a data extraction template and piloted the
form on ten reviews. Two of the piloted reviews were
not eligible for this study, but we used them because
they had been defined by the Canadian Institutes of
Health Research [87] as exemplar Cochrane reviews re-
garding the consideration of sex and gender. The data
extraction template is available upon request.
We extracted data with the EPPI-Reviewer 4 software [85].
At least two authors (JLA, ES, AF or SCN) extracted the
data for each item of the form. For critical items, two authors
extracted data independently. For other items, one author
extracted the data, and another author cross-checked the in-
formation extracted. We resolved discrepancies by consen-
sus. In the case of no consensus, a third author intervened.
We did not contact the review authors to obtain missing in-
formation or clarification.
Next, we detail the methods used to complete each
specific objective.
Analysis methods
Objective 1. To describe and assess the terminology and
definitions used for sex and gender
We described the terms used for sex and gender and the sec-
tions in which these terms appeared. Moreover, we assessed
the appropriateness of the terms and definitions used by
comparing them with the proposals of the SAGER (Reporting
of Sex and Gender Equity in Research) guidelines [16]. We
followed the classifications detailed in Tables 1 and 2. See
also Additional file 1 for sex and gender definitions.
Objective 2. To determine the content of the reviews about
sex and gender
We determined the sex and gender content of each review
according to the domains proposed by the Sex and Gen-
der Appraisal Tool for Systematic Reviews (SGAT-SR) [14].
This 21-item tool assesses how a Cochrane review has
considered sex and gender. It appraises seven review
Table 1 Classification of the sex and gender terms
Classification
Correct Any of the following.
1. Male or female for sex and an adequate definition of sex (biological).
2. Men or women for gender and an adequate definition of gender (cultural and socially determined roles).
Incorrect Any of the following.
1. Male or female for gender.
2. Men or women for sex.
Unclear Any of the following.
1. Terms for sex or gender used without defining sex or gender. For example, if a review stated that the sex of the participants was
male (56%) and female (64%), but there was no definition for sex, we judged the terminology as unclear because we could not know
that the review was referring to sex or gender.
2. Terms inconsistently used in the review. For example, the review used the terms ‘male’ and ‘men’ for the same concept.
3. Abbreviations used without the full term provided.
Not
applicable
No mention to sex or gender
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sections: (a) Background, (b) Objectives, (c) Criteria for in-
clusion/exclusion, (d) Methods, (e) Results and analysis,
(f) Discussion and conclusions, and (g) Table of included
studies. Each question of the tool has four answers: (a)
“Yes, review met criteria”; (b) “No, the review did not
meet criteria”; (c) “Item was not applicable to review”; or
(d) “Unable to determine”. The tool allows adding free
text comments to each response in case of need. We made
minor wording changes to the SGAT-SR. Additional file 4
shows the domains of the tool and the guidance on which
we based our judgements.
We tabulated the responses to the tool by simple
counts, and summarised the results numerically to pro-
vide an indication of overall responses (as done by Doull
et al. [14] in a methodology study that used the
SGAT-SR to examine the consideration of sex and gen-
der in a sample of Cochrane reviews in the area of car-
diovascular health). We calculated the percentage of
reviews meeting each item only when this was applicable
(Number of reviews meeting item × 100/Total number
of included reviews in which the item was applicable);
thus, when an item was not applicable for a review, that
review was considered neither in the numerator nor in
the denominator for that item. This omission applied to
reviews focusing on females only, that is, those reviews
addressing pregnancy and delivery. Breast cancer was
not the case, as it can also affect males.
Two authors (SCN, JLA, ES, or AFC) independently an-
swered each item of the tool not masked to the review de-
tails. We resolved disagreements through discussion and
by consulting a third author if there was no consensus.
We tabulated the judgements of the SGAT-SR and used
Powerpoint 2016 [88] and Review Manager 5.3 [89] to
summarise our judgements graphically.
Objective 3. To describe the SGBA of the reviews
Objective 3a. To describe the reporting of the sex
and the gender characteristics of the study
participants We described if the review had attempted
to report the sex and gender characteristics of the partic-
ipants recruited for each included study. For a review to
describe the study samples accurately, we agreed that it
should have attempted to report at least the following
information for each included study (based on Clayton
et al. [90]). We will report the following key sex and
gender characteristics.
• Sex measurement (ascertained by genotyping of
blood sample)
• Number of female and male participants
• Gender measurement (ascertained by self-report)
• Number of women and men participants
We focused on the information that the review re-
ported in the table of included studies. We classified the
review reporting of the sex and gender characteristics of
the study participants according to the following
categories.
• Correct with a complete description: the review
attempted to describe all the key sex and gender charac-
teristics, and this information was available for all the in-
cluded studies.
• Correct with an incomplete description: the review
attempted to describe all the key sex and gender charac-
teristics, but this information was not available for all
the included studies, which was highlighted by the re-
view authors.
• Incorrect: the review did not attempt to describe all
the key sex and gender characteristics for all the in-
cluded studies.
Objective 3b. To describe the SGBA in the reviews
First, we identified the SRs that had planned or used any
SGBA. Second, we described the SGBA methods
planned and finally used. We considered Welch et al. [4]
to describe the SGBA methods used:
• Subgroup analysis-pooled results: SRs that assessed
impacts of health interventions on the outcome using
subgroup analysis with pooling.
• Subgroup analysis-descriptive: SRs that described
within-study differences without pooling.
• Targeted analyses of sex or gender populations
• Other methods used for SGBA
Objective 4. To assess whether the review conclusions
considered the sex- and gender-related findings
We calculated the percentage of reviews considering the
sex- and gender-related findings in the conclusions, in
particular:
 % of reviews considering sex or gender findings in
the “Implications for clinical practice” section
Table 2 Classification of the sex and gender definitions
Classification
Correct Definitions like SAGER guidelines
Incorrect Definitions different to SAGER guidelines
Unclear Terms for sex or gender used without a definition for sex or gender
Not applicable There was no mention of sex or gender in the review
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 % of reviews considering sex or gender findings in
the “Implications for research” section
 % of reviews performing SGBA that considered sex
or gender findings in the “Implications for clinical
practice” section
 % of reviews performing SGBA that considered sex
or gender findings in the “Implications for research”
section
Results
Results of the search
The search strategy in CDSR generated 7156 records.
First, we screened their titles and abstracts, and we ex-
cluded 6836 records because they were not eligible. Sec-
ond, we subsequently retrieved 320 full texts for further
examination. We excluded 207 full texts (see reasons in
Fig. 1), and we finally included 113 reviews.
Description of the included reviews
This study included 113 reviews (see Additional file 5, also
available in RIS format upon demand). The reviews were
published between 2003 and 2016 within 23 different
Cochrane Review Groups. The Cochrane Wounds Group
was the review group with the most reviews included in
this study (35/113 reviews [31%]), followed by the Anaes-
thesia, Critical, and Emergency Care Group (13/113 re-
views [12%]), and the Incontinence Group (10/113
reviews [9%]). Each of the remaining Cochrane Review
Groups published less than ten of the included reviews.
All the reviews evaluated the effects of interventions for
preventing HAIs. The interventions most frequently eval-
uated were those aiming to prevent HAIs associated to
surgery (50/113 [44%] reviews), followed by interventions
to prevent infections associated to vascular accesses (21/
113 [19%] reviews), and interventions based on patient
and healthcare personnel hygiene (14/113 [12%] reviews).
Other interventions evaluated were, for example, those to
prevent urinary catheter-associated infection, education
and training to prevent HAIs, or interventions to prevent
infection associated with dental procedures.
All the reviews planned to assess at least one of our
study outcomes. HAI was defined as eligible in 105/113
(93%) reviews, followed by total mortality (66/113 re-
views [58%]), surrogate measures of HAI (31/113 re-
views [27%]), colonisation (19/113 reviews [17%]),
mortality due to HAI (15/113 reviews [13%]), and resist-
ance to antimicrobials (14/113 reviews [12%]).
The most common study design was the randomised
controlled trial (RCT), which was eligible in all the in-
cluded reviews (100%). The RCT was the only study de-
sign eligible in 57 reviews (50%), but another 55 reviews
(49%) admitted the inclusion of at least one type of
non-randomised study (NRS) as well. For one review
(1%), it was unclear if NRS were eligible.
Objective 1. To describe and assess the terminology and
definitions used for sex and gender
100/113 reviews (88%) used at least one sex or
gender-related term. The terms used varied, and no re-
view made it explicit that sex and gender were different
concepts. ‘Sex’ was the term used in the most reviews
(58/113 reviews, 51%), followed by ‘male’ (54/113 re-
views, 48%), ‘woman’ or ‘women’ (53/113 reviews, 47%),
‘female’ (50/113 reviews, 44%), ‘gender’ (42/113 reviews,
37%), ‘men’ or ‘man’ (28/113 reviews, 25%), or other
terms, in particular ‘boys’ and ‘girls’ (3/113 reviews, 3%).
Fig. 1 Flow diagram of the selection process
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13/113 reviews (12%) used no term related to sex nor
gender.
The terms appeared mainly in the ‘Characteristics of
studies’ section (84/113 reviews, 74%). On the other
hand, only 10/113 (9%) reviews used these terms in the
conclusions section. Table 3 details the review sections
that used these terms.
The reviews defined neither sex nor gender. Thus we
could not assess the definitions provided. Moreover, the
absence of definitions hindered our attempt to assess the
appropriateness of the terms used. For thirteen reviews
it was not applicable to assess the terminology because
they did not use sex or gender terms. Another 11/100
(11%) reviews used incorrect terms: ‘male’ or ‘female’ for
gender (8 reviews), and ‘men’ or ‘women’ for sex (3 re-
views). Also, 89/100 reviews (89%) used unclear termin-
ology because there was no definition for sex or gender
(80 reviews), because both sex and gender terms were
used inconsistently apparently for the same concepts
(eight reviews), or because the abbreviation “M” was
used without detailing the full term (one review). Rea-
sons to judge the terms as unclear or incorrect are
shown in Fig. 2.
Objective 2. To determine the content of the reviews
about sex and gender
We did not determine the sex and gender content for
eleven reviews [91–101] as they included females only
due to the topics addressed, that is, interventions to pre-
vent HAIs in caesarean section, operative vaginal deliv-
ery, abortion, amniotomy, or prelabour rupture of
membranes. Table 4 details the overall responses to the
SGAT-SR questions, and Additional files 6 and 7 detail
our responses to the tool for each review, which can be
seen graphically in Fig. 3.
No review met all the applicable items of the
SGAT-SR. In fact, 51/102 reviews (50%) fulfilled none of
the applicable items. The remaining reviews fulfilled one
(38/102 reviews [37%]), two (9/102 [9%]), three (3/102
[3%)], or four (1/102 [1%]) of the applicable items.
Review section: background
12/102 reviews (12%) used sex or gender-related terms
in the background. However, only 2/102 reviews (2%)
defined the relevance of sex or gender to the review
question, and this was unclear for 8/102 reviews (8%).
No review (0/102) discussed in its background why sex
or gender differences might be expected.
Review section: objectives
No review (0/102 reviews) used the terms sex, gender,
male, or female in the objectives.
Review section: criteria for inclusion/exclusion
No review used sex or gender as criteria for deciding on
study eligibility (0/102 reviews) or explained why to con-
sider sex or gender differences for study eligibility (0/102
reviews).
Review section: methods
No review (0/102 reviews) planned to examine or finally
examined whether outcome measures were different for
males and females. No review planned to extract or ex-
tracted data by sex (0/102 reviews). No review extracted
withdrawals and dropouts by sex (0/102 reviews). No re-
view used sex/gender as a proxy for other measures (0/
102 reviews).
Table 3 Percentage of reviews using sex and gender terms in each review section
Review section Sex Gender Malea Femaleb Menc Womend Other
Abstract 2% – – 1% 2% 8% –
Background 3% 1% 4% 5% 3% 15% –
Plain language summary 2% 1% 2% – 8% –
Eligibility criteria 4% 8% 1% 1% 4% 13% –
Search methods – – – – – 1% –
Data collection and analysis 12% 12% 4% 4% 5% 9% –
Results 9% 10% 12% 12% 7% 18% 1%
Discussion 4% 2% 2% 1% 4% 15% –
Authors’ conclusions 1% – – 1% 1% 7% –
Characteristics of studies 31% 22% 42% 35% 13% 35% 2%
Other sections 5% 3% – – – 3% –
Not reported 49% 63% 52% 56% 75% 53% 97%
a‘Male’, ‘males’ or ‘m’
b‘Female’, ‘females’ or ‘f
c‘Men’ or ‘man’ or ‘m’
d‘Women’ or woman
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Fig. 2 Appropriateness of the sex and gender terminology
Table 4 Responses to the Sex and Gender Appraisal Tool for Systematic Reviews (SGAT-SR)
Reviews meeting the
criteria (n)
Tool question Reviews meeting the criteria (n)




1.Background 1.1. Are the terms sex and gender used in the background? 12 90 0 11
1.2. Are sex/gender identified as relevant or not to review question? 2 92 8 11
1.3. Does background discuss why sex/gender differences may be expected? 0 102 0 11
2. Objectives 2.1. Are the terms sex, gender, male, or female used in objectives? 0 102 0 11
3.Criteria for inclusion-
exclusion
3.1. Do the review’s inclusion-exclusion criteria consider sex-gender
differences?
0 102 0 11
3.2. Was there justification or explanation for the exclusion of some groups? 0 102 0 11
4. Methods 4.1. Does the review examine whether outcome measures are different for
males and females?
0 102 0 11
4.2. Did the review extract data by sex? 0 102 0 11
4.3. Did the review extract data on sex of withdrawals and dropouts? 0 102 0 11
4.4. In cases where sex/gender is used as a proxy, is there an explanation? 0 0 0 113
4.5. Were any subgroup analyses completed? 41 61 0 11
4.6. Were subgroup analyses by sex completed? 3 99 0 11
5.Results and analysis 5.1. Do results distinguish between findings for males/females? 0 96 1 16
5.2. Does the review report conclusions that are different for men and
women?
0 96 1 16
5.3. If adverse effects are reported, is information sex-disaggregated? 0 60 0 53
5.4. Does review note that subgroup analyses by sex could not be done? 7 3 1 102
6. Discussion and
conclusion
6.1. Does the review report that primary studies analysed or failed to analyse
results by sex?
0 97 0 16
6.2. Does the review address sex/gender implications for clinical practice? 1 101 0 11
6.3. Does the review address sex/gender implications for policy and
regulation?
0 102 0 11
6.4. Does the review address sex/gender implications for research? 2 100 0 11
7. Table of included
studies
7.1. Detailed information on sex/gender of the study samples? 0 97 0 16
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86/102 reviews (84%) planned to perform subgroup
analysis, but only 41/102 reviews (40%) could complete
at least one subgroup analysis. 10/102 reviews (10%)
chose sex as the factor to analyse, but only three (3/102
[3%]) could complete the analysis.
Review section: results and analysis
No review in which it was applicable distinguished between
findings for males and females (0/97), or reported conclu-
sions (of effectiveness, efficacy, safety) that were different for
men and women (0/97 reviews). For one review [102] we
judged that these two items of the tool were unclear because
the results and conclusions were reported separately only for
some review outcomes. For sixteen reviews it was not applic-
able to assess these items because they focused on one sex
only (11 reviews), or they included no study (6 reviews).
No review (0/60 reviews) reported adverse effects dis-
aggregated by sex. For the remaining 53 reviews, it was
not applicable to assess this item of the tool due to the
following reasons: the reviews focused on one sex only
(11 reviews), they included no study (6 reviews), they did
not plan to assess adverse effects (33 reviews), or al-
though they planned to assess safety the included studies
did not report adverse effects (9 reviews).
Seven out of the ten reviews (70%) that planned but
could not perform subgroup analysis by sex explained
why this analysis could not be completed.
Review section: discussion and conclusions
No review in which it was applicable (0/97 reviews) re-
ported if the included studies had analysed or failed to
analyse results by sex. This aspect was not applicable in
16 reviews because they had no included studies (6 re-
views) or because they focused on one sex only (11
reviews).
A total of 3/102 reviews (3%) considered sex/gender impli-
cations in their conclusions: 1/102 review (1%) addressed the
implications for clinical practice, and the other 2/102 reviews
(2%) considered the implications for research. However, no
review addressed the implications of sex/gender for policy
and regulation.
Review section: table of included studies
No review (0/97 reviews [0%]) provided detailed in-
formation on the sex and the gender of the samples
of all the included studies. For sixteen reviews, this
was not applicable as they did not include any study
(six reviews) or they focused on one sex only (eleven
reviews).
Regarding the sex of the participants recruited, 78/97
reviews (80%) provided no information at all. Another
19/97 reviews (20%) provided unclear information. Re-
garding the gender, 87/97 reviews (90%) provided no in-
formation, and in the other 10/97 reviews (10%) the
information was unclear. We considered that the infor-
mation about the sex or gender of the recruited samples
was unclear for several reasons: there was no definition
for sex or gender, the authors used sex or gender terms
but they did not state if they referred to sex or gender,
or the authors misused the terms (men or women for
sex, or male or female for gender).
Fig. 3 Sex and gender appraisal graph. Judgements across reviews for each item of the tool
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Objective 3. To describe the SGBA of the included reviews
Objective 3a. To describe the reporting of the sex
and the gender characteristics of the study
participants The review reporting of the sex and gender
characteristics of the study participants was always in-
correct, as no review attempted to report the sex or the
gender of the participants of all the included studies.
The method to ascertain the sex or gender of the re-
cruited participants was never reported in the reviews.
Objective 3b. Description of the SGBA in the
included reviews Ten reviews (10/102 [10%]) planned
to perform SGBA, but only three (3/102 [3%]) could
complete the analysis. The method chosen for SGBA
was always the use of subgroup analysis based on sex
(one review) or gender (two reviews). Two reviews per-
formed subgroup analysis by pooling results of studies
to assess the effect of sex or gender on the outcome, and
the other review performed a descriptive subgroup ana-
lysis, that is, described within-study differences by gen-
der without pooling.
Objective 4. To assess whether the review conclusions
considered the sex- and gender-related findings
Only 3/102 reviews (3%) [102–104] considered the
sex or gender-related findings in the conclusions.
One of them mentioned the sex/gender implications
for clinical practice by stating that “Siliconised cath-
eters may be less likely to cause urethral side effects
in men” [102]. The other two reviews considered the
implications of sex/gender for research by stating
that “sub-group analysis would give valuable data as
to whether certain policies are more effective in
sub-groups such as females” [103], or “Future trials
comparing suprapubic and intermittent urethral
catheterisation for short-term use in hospitalised
men should be conducted [...]” [104]. However, no
review addressed the implications of sex/gender for
policy and regulation. Table 5 details how the re-
views considered sex or gender findings in their
conclusions.
Discussion
Summary of main results
One hundred thirteen Cochrane reviews assessed the ef-
fects of interventions to prevent HAIs. Consideration of
sex and gender in these reviews was practically absent.
Several reasons may explain this inattention.
First, SRs may replicate limitations or gaps in primary
studies regarding their research question, their data ana-
lysis, and the interpretation of their results [14]. Primary
studies of hospital infection control interventions usually
ignore sex, gender or having a gender identity that does
not match one’s biological sex. Several reasons can ex-
plain this inattention. For example, researchers may con-
sider that making conclusions about these factors is
challenging because hospital-based studies are often
based on small sample sizes. Moreover, it is probably un-
feasible for retrospective large primary studies, or those
based on electronic records, to capture gender and sex
differences because they are based on data sources that
have not collected vital information, such as the assess-
ment of biological sex by genotyping or the gender
measurement by self-report. As a consequence, the in-
cluded studies may not have reported the sex and gender
distributions of the recruited samples. Alternatively, the
authors may have just detailed that the study groups had
equal numbers of males and females at baseline as a proxy
for the randomisation success. Thus, sex was “controlled
for” in the primary studies rather than considered to assess
how the study outcomes vary across sex or gender groups
[5]. Our study did not assess the data provided by the pri-
mary studies, so we cannot confirm this. Nevertheless,
other studies have highlighted that RCTs do not usually
provide sex or gender disaggregated data [14, 36, 105–109],
and that sex/gender policies have not resulted in significant
increases in reporting results by sex [36]. On the other
hand, the SRs included in our study did not even plan to
perform any SGBA, so we think the lack of data in the in-
cluded studies cannot entirely explain their lack of attention
to sex and gender.
Second, Cochrane launched the SGSR-AT [110] in
2011, that is, the Cochrane guidance to integrate sex and
gender in SRs is quite recent. Thus, the guidance was
not available at the time of writing the protocols of the
included reviews. In fact, 31 included reviews (27%) were
Table 5 Reviews considering sex or gender findings in the conclusions
% reviews (n/total number of
reviews)
Reviews considering sex or gender findings in the “Implications for clinical practice” section 1% (1/102)
Reviews considering sex or gender findings in the “Implications for research” section 2% (2/102)
Reviews performing SGBA that considered sex or gender findings in the “Implications for clinical practice”
section
33% (1/3)
Reviews performing SGBA that considered sex or gender findings in the “Implications for research” section 33% (1/3)
SGBA sex- and gender-based analysis
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published in 2011 or before, and the 43 SRs published
from 2012 to 2014 probably did not consider this guid-
ance at their protocol stage.
Third, the authors of the included SRs may have
thought that sex/gender was not a relevant factor to
consider when evaluating the effects of interventions to
prevent HAIs. Again, this is possible, but we cannot con-
firm that this was the case as the review authors did not
make this assumption explicit in the reviews.
Fourth, the review authors did not even consider the
role of sex/gender while planning the review. This situ-
ation is, in our opinion, the most plausible explanation
and the most worrying one, as it denotes a knowledge
gap about the potential relevance of sex and gender in
these reviews.
Overall completeness and applicability of evidence
This study aimed to describe the extent to which Cochrane
reviews of interventions for preventing HAIs consider sex
and gender. We are quite confident that we have achieved
our goal. Firstly, we have identified all the Cochrane reviews
of interventions to prevent HAIs (we did not rely on a sam-
ple of Cochrane reviews), and secondly, we have demon-
strated that SGBA is practically absent in these reviews.
Our study findings apply only to Cochrane reviews of in-
terventions to prevent HAIs. Thus, we cannot infer that our
study findings can be applied to Cochrane reviews of other
health topics, or to non-Cochrane reviews. First, other
Cochrane reviews may have incorporated the guidance of
the Sex/Gender Methods Group [111]. Second, many inter-
ventions to prevent HAIs are non-pharmacological, for ex-
ample, the use of gloves or hand washing. The methods used
to evaluate non-pharmacological interventions may differ
from those applied to evaluate drugs, and this may imply a
different approach to consider sex and gender. Third, there
are other health areas where the consideration of the rele-
vance of sex and gender may be more common than in in-
fection control research.
The findings of this study are relevant and confirm
that the reviews did not consider the sex and the gender
of the body of the evidence synthesised. Thus, these re-
views do not provide critical information to judge the
applicability of the results to the target population [112].
Also, the sex and gender characteristics should have
been considered to judge the “indirectness” of the evi-
dence with the GRADE (Grading of Recommendations
Assessment, Development and Evaluation) system, and
therefore, to rate the quality of that evidence [113]; how-
ever, we have demonstrated that this was not the case.
The tables of characteristics of the included studies are
essential to describe the sex and the gender of the sub-
jects considered within each study. In our opinion, the
relevant information is the sex and gender characteris-
tics of the sample from which the study results were
obtained (and not the inclusion criteria of the study).
However, specific guidance to collect and report this in-
formation in Cochrane reviews is still lacking.
Strengths and limitations of this study
Strengths
We made efforts to identify all the Cochrane reviews
assessing the effects of interventions to prevent HAIs. We
obtained all the Cochrane reviews published in CDSR
until December 31st, 2016 and screened all these records.
To minimise bias, at least two authors independently par-
ticipated in the selection process, and, in case of disagree-
ment, a third author was consulted. We also defined and
applied explicit exclusion criteria which made the process
even more rigorous.
We determined the sex/gender content of each review
with the SGAT-SR. Again, to minimise bias, at least two
reviewers (JLA and ES or SCN) independently partici-
pated in the assessment. In case of disagreement, a third
reviewer (JZ) was consulted. Furthermore, to improve
the consistency we piloted the tool with several reviews,
and we prepared a user guide.
The SGAT-SR helped us to assess how the different
Cochrane review sections had considered sex and gender.
We chose this tool because it is recommended by the Sex/
Gender Cochrane Working Group [54]. Moreover, we per-
formed an extensive search up to April 2017 that revealed a
lack of additional sex- and gender-specific appraisal tools
for SRs. As the tool had already been used to assess SRs on
cardiovascular diseases, we were able to better understand
the tool’s content by comparing our judgments with those
presented in the published article [14]. Independent subject
experts had also reviewed the tool to ensure consistency
with common understandings of the concepts of sex and
gender and to ensure compatibility with Cochrane review
format and style [14].
Limitations
This study aimed to assess how the reviews had been con-
ducted, and not how they had been reported. However, we
did not write to the review authors to obtain any missing,
incomplete, or unclear information. Thus, we made as-
sumptions for information that was not clear by reading
the review: we generally considered that the lack of report-
ing of a particular aspect meant that this was not done.
However, this may not represent what the reviewers did.
During the selection and data extraction processes, we
were not masked to the review team or institution. More-
over, JLA and SCN were the authors of this methodology
study and three of the included reviews [114–116]. How-
ever, we prevented that this fact influenced the decisions,
as the selection and extraction processes were done by at
least two authors independently, and, in case of disagree-
ment, we consulted a third author.
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We did not measure the reliability of the SGAT-SR
judgements (for example, by obtaining the kappa statistic),
so we cannot confirm that our decisions were reliable.
We encountered some challenges with the use of the
SGAT-SR. First, the tool needs to be more operative and
manageable, that is, it should provide specific guidance
with examples taken from other reviews. Second, it is
not clear if some items of the tool refer to the planning
of the review or to what the review finally did. Third,
the tool should suggest when an item is not applicable;
for example, for reviews with no included studies, it is
not clear if the items related to the results must be an-
swered as “not meeting the criteria” or as “not applic-
able”. Fourth, the tool does not allow explicit assessment
on the dimension of sex and the dimension of gender
separately. It gathers both dimensions in the same ques-
tions. We think that each of these two domains warrants
a focused appraisal. Fifth, the tool does not assess rele-
vant sections of a Cochrane review, such as the abstract,
the plain language summary, the discussion, or the sum-
mary of findings tables.
As stated in the methods section, we considered that
it was not applicable to use the SGAT-ST for reviews of
topics focused on one sex, such as pregnancy or delivery.
We decided this because we felt that the SGAT-SR was
not developed to assess both features, sex and gender,
separately. However, although it did not apply to the as-
sessment of the sex content for these reviews, it was still
relevant to assess how the gender was addressed.
Finally, it is noteworthy that although sex and gender are
important factors in clinical research [90], more work is
needed to standardise the way sex and gender are measured
and reported, and the methods to determine how these fac-
tors influence health and health care [90]). There is no con-
sensus on how to disaggregate demographic and outcome
data by sex, gender, or both, or on how to report this infor-
mation. Therefore, the report of crucial information on sex,
gender, or both, is incomplete in primary studies and system-
atic reviews. In the end, this lack of consensus moves away
from a personalised medicine approach.
Agreements and disagreements with other studies or
reviews
Our results are consistent with another study describing
the consideration of SGBA in Cochrane reviews in the
area of cardiovascular health [14], which also concluded
that SGBA was practically absent in this sample of
Cochrane reviews. In this line, our study supports the
idea that current Cochrane reviews do not consider sex
and gender, and that there is much room for improve-
ment in this aspect. It is also noteworthy that, to our
knowledge, only one study has appraised the SGBA done
in Cochrane reviews [14].
This gap does not only affect Cochrane reviews, as it is
also present in non-Cochrane ones. In fact, SRs do not often
analyse or report equity issues in general [38, 46–49], and
sex/gender in particular [17, 25, 26, 33, 35].
Conclusions
Main conclusions of this study
Consideration of sex and gender in Cochrane reviews of
interventions for preventing HAIs was practically absent.
This lack of attention to sex and gender reduces the
quality of Cochrane reviews, and the applicability of
their results for all people: women and men, boys and
girls, and people of diverse gender identities.
Recommendations derived from this study
Cochrane should map the consideration of sex and gender
in all Cochrane reviews and, if necessary, plan how to ad-
dress the shortfalls detected efficiently.
Cochrane should continue encouraging review authors
to consider sex and gender in their reviews.
The SGAT-SR helps to assess how sex and gender
have been considered in a Cochrane review, although
this tool has some room for improvement.
Cochrane should provide review authors with more opera-
tive guidance to consider sex and gender in Cochrane reviews.
Cochrane guidance to consider sex and gender in
Cochrane reviews should be updated, validated, and re-
quired to meet the Methodological Expectations of
Cochrane Intervention Reviews (MECIR) standards.
Primary studies should consider sex and gender differences
in their research questions, data, analyses, interpretation and
reporting of the study results. This approach will facilitate
the consideration of sex and gender in systematic reviews
and meta-analyses.
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